Sex-Divergent Effects of Magnesium L-Threonate Supplementation on Sleep Quality, Cognitive Performance, and Neuromuscular Function in Healthy Adults

NCT07706283 | Completed

• 1 other identifier: 2368924-3
• Study Type: interventional
• Target: 81
• Locations: 1 country
• Sites: 1

Brief Summary

This study examined the effects of six weeks of magnesium L-threonate (MgT) supplementation on sleep quality, cognitive performance under experimentally induced mental fatigue, neuromuscular function, and psychophysiological outcomes in healthy adults. Biological sex and weight status were examined as pre-specified moderating variables.

Conditions

Healthy Adults; Cognitive Performance; Sleep Quality; Neuromuscular Function

Keywords

magnesium L-threonate; mental fatigue; sleep quality; neuromuscular function; sex differences; countermovement jump; cognitive performance; ergogenic supplementation

Outcome Measures

Primary Outcomes (3)

• Pittsburgh Sleep Quality Index (PSQI)

  Subjective sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI; scored 0-21). Higher scores indicate poorer sleep quality. A score ≥5 indicates poor sleep quality.

  Baseline (Week 0) and post-intervention (Week 6)

• Flanker Task Reaction Time

  Reaction time (ms) on the Incongruent Flanker Task assessed via computerized cognitive battery (SOMA platform). Lower values indicate faster processing.

  Baseline (Week 0) and post-intervention (Week 6), assessed before and after a 20-minute mental fatigue induction protocol at each visit

• Countermovement Jump Height

  Jump height (cm) assessed via dual force plates (VALD ForceDecks). Higher values indicate greater neuromuscular performance.

  Baseline (Week 0) and post-intervention (Week 6), assessed before and after a 20-minute mental fatigue induction protocol at each visit

Secondary Outcomes (22)

• Flanker Task Processing Speed

  Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

• Flanker Task Rate Correct Score

  Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

• Flanker Task Coefficient of Variation

  Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

• Stroop Task Reaction Time

  Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

• Stroop Task Processing Speed

  Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

Study Arms (2)

Magnesium L-Threonate (MgT)

EXPERIMENTAL

Participants consumed 2 g·day-¹ of magnesium L-threonate (Magtein®; AIDP Inc., City of Industry, CA, USA) once daily for six weeks.

Dietary Supplement: Magnesium L-threonate

Placebo

PLACEBO COMPARATOR

Participants consumed visually identical capsules containing rice powder (1.4 g·day-¹) once daily for six weeks. Capsules were matched to the intervention in appearance and dosing schedule.

Dietary Supplement: Placebo

Interventions

Magnesium L-threonate DIETARY_SUPPLEMENT

Magnesium L-threonate

Also known as: Magtein®

Magnesium L-Threonate (MgT)

Placebo DIETARY_SUPPLEMENT

Rice powder

Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male or female adults aged 18-45 years
• Free from diagnosed neurological, cardiovascular, metabolic, or psychiatric conditions
• Not currently taking medications or supplements known to influence cognitive or neuromuscular function
• Willing to maintain habitual diet, physical activity, and sleep routines throughout the study period

You may not qualify if:

• Pregnant or breastfeeding
• Diagnosed sleep disorder
• Initiated any new supplement or medication regimen within the past three months

Sponsors & Collaborators

• Barry University: lead

Study Sites (1)

Barry University

Miami Shores, Florida, 33161, United States

Location

MeSH Terms

Conditions

Sleep Initiation and Maintenance Disorders; Mental Fatigue

Interventions

threonic acid

Condition Hierarchy (Ancestors)

Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases; Mental Disorders; Fatigue; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Behavioral Symptoms; Behavior

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Supplements were pre-labeled by batch number by an external party not involved in data collection. Capsules were visually identical in appearance. Group assignment was not disclosed to participants or study personnel until completion of all data collection and analysis.
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor of Sport and Exercise Science

Study Record Dates

• First Submitted: July 11, 2026
• First Posted: July 15, 2026
• Study Start: December 1, 2025
• Primary Completion: March 19, 2026
• Study Completion: March 19, 2026
• Last Updated: July 15, 2026

Record last verified: 2026-07

Locations

US (1)